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Abstract. Long‑term administration of glucocorticoid
hormones is considered one of predominant pathological
factors inducing osteonecrosis of the femoral head (ONFH)
development and progression, in which reduction of blood
supply leads to a progressive bone loss and impairment of
bone structure in the majority of cases. In a non‑hematopoietic
system, erythropoietin (EPO) can stimulate angiogenesis and
bone regeneration. However, the specific mechanism underlying the role of EPO in ONFH remains to be elucidated.
Therefore, the purpose of this study was to determine the
effect of EPO on the prevention of bone loss in ONFH. Male
C57BL/6J mice 3 months old were divided into two groups:
EPO group and control groups. ONFH was established by
the administration prednisolone (PDS, 100 mg/kg) with
co‑treatment of lipopolysaccharide (LPS, 1 mg/kg). ONFH
mice received recombinant mouse EPO (500 U/kg/day) or
saline intramuscularly. The mice were sacrificed at 2, 4, 6 and
8 weeks following the initiation of treatment. Alterations in the
general architecture and histomorphology of the right femoral
head were determined by hematoxylin and eosin staining and
micro computed tomography (micro‑CT). The expression
of runt‑related transcription factor 2 (Runx2), osteocalcin,
vascular endothelial growth factor (VEGF) and platelet
endothelial cell adhesion molecule (CD31) in the femoral head
was tested by immunohistochemistry. Terminal deoxynucleotidyl‑transferase‑mediated dUTP nick end labeling (TUNEL)
assay was performed to detect apoptosis in femoral heads.
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Micro‑CT data revealed that EPO significantly improved
bone volume/total volume and bone mineral density following
6 and 8 weeks of treatment. Histological analysis further
demonstrated that EPO treatment improved the arrangement
of trabeculae, thinning of trabeculae and other fractures in
femoral heads, especially following 6 and 8 weeks of treatment. Immunohistochemical analysis suggested that EPO
treatment up‑regulated the expressions of Runx2, osteocalcin,
VEGF and CD31 at 4 and 8 weeks. The TUNEL apoptosis
assay suggested that EPO intervention reduced apoptosis in
avascular ONFH. Therefore, EPO prevents bone loss in ONFH
in mice through enhancing Runx2‑mediated osteogenesis,
VEGF‑mediated angiogenesis and inhibition of cell apoptosis.
Introduction
Osteonecrosis of the femoral head (ONFH) is a common and
progressive disease that predominantly impairs the femoral
head (1). With the development of the pathological process, it
often progresses and leads to the collapse of the femoral head
and osteoarthritis. Late stages of ONFH cause severe pain and
require surgical arthrodesis, which severely affects the quality
of life and the ability to work, and simultaneously causes
economic burden for patients and society. Although multiple
factors have been demonstrated to contribute to ONFN,
long‑term administration of glucocorticoid hormones (GCs)
is considered a predominant cause. Currently, surgery is the
primary treatment option, which can markedly improve the
symptoms among young and middle‑age patients. However,
multiple revision surgeries are frequently required during the
lifetime of the patient. Therefore, there is a need to develop
novel medical therapies for the treatment of ONFH.
Erythropoietin (EPO), a pleiotropic cytokine mainly
secreted by kidneys, stimulates the production of red blood
cells (2). Previous studies reported beneficial effects of EPO
on the non‑hematopoietic system and on the bone fracture
repair process, including stimulation of angiogenesis and bone
formation (3,4). Moreover, Bakhshi et al (5) hypothesized that
local administration of recombinant human erythropoietin
(rhEPO) combined with core decompression surgery can
enhance angiogenesis and bone regeneration in the early
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stages of ONFH. However, the mechanism underlying the role
of EPO on ONFH remain to be elucidated.
The pathomechanism underlying avascular necrosis of the
femoral head induced by steroids can be ultimately ascribed to
the damage of the local vasculature and restriction of oxygen
supply to the femoral head (6). Vascularization in bone tissue
supplies nutrients for the normal metabolic process, and angiogenesis is essential for bone tissue regeneration in the necrotic
area of the femoral head. Vascular endothelial growth factor
(VEGF) regulates the coupling of angiogenesis and bone
formation, and regeneration (7). It has been demonstrated
that EPO serves an important role in capillary vessel formation and up‑regulation of VEGF mRNA expression during
tendon repair (8). In addition, studies have demonstrated that
GCs can induce apoptosis of osteoblasts or osteocytes in the
steroid‑induced ONFH (9,10).
Therefore, the authors of the present study hypothesized that
the administration of EPO prevents bone loss in a mouse model
of ONFH by increasing osteocalcin‑ and vascular endothelial
growth factor (VEGF)‑mediated angiogenesis, up‑regulating
runt‑related transcription factor 2 (Runx2)‑mediated osteogenesis and inhibiting cell apoptosis.
Materials and methods
Animals. In the present study, male C57BL/6J mice (weight,
23.5‑29.4 g; age, 3 months; n=80) were provided by the
Center of Experimental Animals, Zhejiang Chinese Medical
University (Hangzhou, China). Mice were kept in a temperature‑ and humidity‑controlled environment (22±1˚C, 40‑60%
humidity, atmospheric CO2) with a free access to standard
pellet food and tap water and a 12‑h light/dark cycle. The
present study was approved by the local Governmental Animal
Care Committee (Hangzhou, China) and all the experimental
procedures adhered to the guidelines set by the Center of
Experimental Animals, Zhejiang Chinese Medical University
(Hangzhou, China).
Model of ONFH. The model of ONFH was established to study
the effect of EPO treatment on ONFH. Mice were randomly and
equally divided into 2 groups: The EPO group and the control
group. The mouse model of ONFH was established by the
administration of prednisolone (PDS; Reyon Pharmaceutical
Co., Ltd., Seoul, Korea) and co‑treatment with lipopolysaccharide (LPS; Sigma‑Aldrich; Merck KGaA, Darmstadt,
Germany), as previously described (11). Intraperitoneal (ip)
administration of LPS (1 mg/kg) was immediately followed
by an intramuscular injection of PDS (100 mg/kg). A second
double‑injection was performed 1 week following the initial
co‑injection of PDS/LPS and injections were continued every
3 days until the mice were sacrificed. The mice in the control
group were treated with the same dosing regimen, using saline
as a substitute for LPS and PDS.
Intervention. Mice in the EPO group were intramuscularly
administered recombinant mouse EPO (500 U/kg/day; cat.
no. 959‑ME‑010; R&D Systems, Inc., Minneapolis, MN,
USA) daily starting 1 week following the initial co‑injection of
PDS/LPS. The mice in the control group were administered an
equivalent amount of saline. At 2, 4, 6 and 8 weeks following

intervention, 6 mice from each group were sacrificed by
carbon dioxide (CO2) narcosis. Subsequently, the mice were
dissected and right femurs were harvested. Following removal
of the skin and muscle from the legs, the entire femur with
the hip joint was removed from the mouse's body by cutting
above the hip joint and in the knee joint. Then the hip joint
was dissected to expose the femoral head and remove the
acetabular tissue. This tissue was used for micro computed
tomography (micro‑CT) and histological analyses.
Micro‑CT analysis. Micro‑CT was performed using a Skyscan
1172X‑ray microtomograph (resolution, 2.47 µm; Bruker
Corporation, Billerica, MA, USA). Femurs were placed vertically in the microtomograph sample holder and images were
captured at 65 kV (153 µA) using a 0.5‑mm aluminum filter. A
series of 483 projection images was captured with a rotation
step of 0.40˚ between each image for each specimen. For each
sample, 3‑dimensional projection images were reconstructed
from a stack of 2‑dimensional images, using the NRecon
software (version 1.6.10; Skyscan; Bruker Corporation). In the
trabecular region of the femoral head, a 0.8x0.8 mm3 region of
interest (ROI) was selected in the center of the femoral head
using a semiautomatic contouring method, and the contouring
of images was performed every 50 axial slices (proximal to
distal). Bone morphometric parameters of ROI, including
tissue volume (TV), bone volume (BV) and bone mineral
density (BMD), were calculated using CTAn analysis software
(version 1.15; Skyscan; Bruker Corporation), as previously
described (12).
Histological analysis. Following harvesting of right femoral
heads, samples were fixed with 10% buffered formalin for
3 days and then decalcified in 14% ethylenediamine tetraacetic
acid for 2 weeks. Decalcified samples were embedded in
paraffin and 3 µm sections were prepared for histological
analysis through haematoxylin and eosin (H&E) staining. The
sections were stained in CAT hematoxylin (no. CATHE‑MM;
Biocare Medical, LLC, Pacheco, CA, USA) for 1 min and counterstained in alcoholic‑eosin (no. 17372‑87‑1; Sigma‑Aldrich;
Merck KGaA) for 1 min. All the procedures were performed at
room temperature. Successful induction of ONFH was defined
as diffuse presence of empty lacunae or pyknotic nuclei of
bone cells in the trabecular bone, accompanied by surrounding
bone marrow cell necrosis (13,14). Histopathological changes
of ONFH were examined under a light microscope (Axio
Scope A1; Carl Zeiss AG, Oberkochen, Germany) in a blinded
manner by three independent investigators. At least 50 lacunae
in each field were counted and 5 fields in each slide were
selected randomly. The fraction of empty lacunae to total
lacunae was defined as the ratio of empty lacuna number to the
total lacuna number. The trabecular bone volume in the area
of femoral heads was measured by Image‑Pro Plus software
(version, 6.0; Media Cybernetics, Inc., Rockville, MD, USA)
and the percentage of trabecular BV/TV of femoral heads was
calculated.
Immunohistochemical analysis. To investigate the expression
levels of Runx2, osteocalcin, VEGF and platelet endothelial cell adhesion molecule (CD31) in femoral heads, bone
sections were prepared for immunohistochemistry. Following
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deparaffinization in xylene and rehydration in a descending
ethanol series (two changes in 100% ethanol, two changes
in 95% ethanol, one change in 70% ethanol, and finally in
distilled water), endogenous peroxidase was quenched by 3%
hydrogen peroxide (H2O2) for 20 min, and antigen retrieval was
performed using 0.01 M citrate buffer [(pH 6.0), 20 min, 95˚C;
cat. no. C02‑02001; Bioss, Beijing, China]. Following blocking
of non‑specific binding sites with a normal goat serum (1:20;
cat. no. C‑0005; Bioss) for 20 min at room temperature, sections
were incubated overnight with mouse monoclonal anti‑Runx2
(Cbfa1; 1:100; cat. no. D130‑3; MBL International Co., Woburn,
MA, USA), rabbit polyclonal anti‑osteocalcin (1 µg/ml; cat.
no. M173; Takara Biotechnology Co., Ltd., Dalian, China),
mouse monoclonal anti‑VEGF (VG‑1; 1:100; cat. no. ab1316;
Abcam, Cambridge, UK) and rabbit polyclonal anti‑CD31
(1:50; cat. no. ARG52748; Arigo Biolaboratories, Hsinchu
City, Taiwan) primary antibodies. Peroxidase‑conjugated
goat anti‑mouse (1:100; cat. no. HA1006; Hangzhou HuAan
Biotechnology Co., Ltd., Hangzhou, China) or peroxidase‑conjugated goat anti‑rabbit (1:1,000; cat. no. GS1001;
Shanghai Good‑Science Biotech Company, Shanghai, China)
immunoglobulin G antibodies were used as secondary
antibodies, respectively. Diaminobenzidine (DAB) served
as a chromogen, and hematoxylin served as a counterstain
(20 sec, at room temperature). Tissue sections were examined
under a light microscope (Zeiss Axio Scope A1, Carl Zeiss
Co, Ltd). A total of 4 randomly‑selected fields from at least
3 different tissue sections were selected for positive staining
quantification. The mean optical density defined as the ratio
of integrated optical density (IOD) to the corresponding cavity
area was calculated using Image‑Pro Plus software.
In order to further investigate angiogenesis, the analysis
of microvessel density (MVD) based on CD31‑positive
staining was performed, as previously described (15). Slides
were examined (magnification, x200) to identify the highest
neovascularization area (hot spot) and a count of individual
microvessels was conducted (magnification, x400). The
brown‑staining single endothelial cells or cell clusters that
visibly separated from adjacent microvessels were defined as a
countable microvessels. The MVD was calculated in five representative areas of each slide. The evaluation was performed in
a blinded manner by three independent investigators.
Terminal deoxynucleotidyl‑transferase‑mediated dUTP nick
end labeling (TUNEL) assay. TUNEL assay was performed
on bone sections using an ApopTag Plus Peroxidase In Situ
Apoptosis kit (cat. no. S7101; EMD Millipore, Billerica, MA,
USA) according to the manufacturer's protocol. Sections
were deparaffinized, pretreated with proteinase K (20 µg/ml;
cat. no. 21627; EMD Millipore) and endogenous peroxidase
was quenched using H 2O2 (3%). Bone sections were incubated with a TdT enzyme (part#90418 from ApopTag Plus
Peroxidase In Situ Apoptosis kit; EMD Millipore), visualized
with DAB detection system (5 min at room temperature) and
counterstained in 0.5% (w/v) methyl green (10 min at room
temperature). Stained sections were visualized under a light
microscope (Zeiss Axio Scope A1, Carl Zeiss Co., Ltd.).
Four randomly‑selected fields from at least 3 different tissue
sections were selected for positive staining quantification and
the apoptosis rate (number of TUNEL‑positive cells/number
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of all cells) was calculated in each section in a blinded manner
by three independent investigators.
Statistical analysis. All data are presented as the
mean ± standard deviation. Following the verification of
normality of distributions and equal variance, comparisons
between groups were performed by Student's t‑test. Statistics
were performed using SPSS software (version 13.0; SPSS
Inc., Chicago, IL, USA). P<0.05 was considered to indicate a
statistically significant difference.
Results
EPO treatment improves the microstructure of the femoral
head in ONFH. The micro‑CT analysis from a 3‑dimensional
reconstruction demonstrated that bone trabeculae of femoral
heads were more finely spread and intact in the EPO group
compared with the control group (Fig. 1A‑J). Trabeculae gradually lost their regular structure and connectivity in the control
group. On the contrary, subchondral trabeculae in the EPO
group maintained their normal structure and gradually recovered at 4, 6 and 8 weeks. The quantitative analysis of micro‑CT
parameters, including BV/TV and BMD, confirmed that the
microstructure of subchondral trabeculae in femoral heads
from the EPO group were improved compared with the control
group following 6 and 8 weeks of treatment (Fig. 1K and L).
In particular, the BV/TV ratio and BMD of femoral heads at
6 and 8 weeks demonstrated significant differences between
the two groups of interest (P<0.05; Fig. 1K and L). However,
BV/TV and BMD did not differ significantly at 2 and 4 weeks
following the EPO or saline treatment. These results suggest
that prolonged administration of EPO can prevent bone loss of
the femoral head in ONFH.
EPO treatment reduces the rate of empty lacunae and
improves the trabecular bone volume in ONFH. As presented
in Fig. 2, histological analysis of the H&E staining revealed
severely thinned and disordered trabeculae, large empty bone
lacunae and numerous pyknotic nuclei of osteocytes in the
femoral heads from the control group, which indicated that an
animal model of ONFH was successfully established (Fig. 2A,
C, E and G). In contrast, the histological analysis of femoral
heads from the EPO group demonstrated that the microstructure of trabeculae gradually recovered (Fig. 2B, D, F and H).
Consistent with the findings of the micro‑CT assay, histological analyses of femoral heads demonstrated that trabecular
bone volume displayed an increasing trend in mice in the EPO
treatment group. Statistical analyses were performed between
groups at multiple time points. BV/TV at 6 and 8 weeks in the
EPO group was increased compared with the control group
at the respective time points (P<0.05; Fig. 2I). In addition, in
the EPO group, BV/TV at 8 weeks was increased compared
with at 2 weeks (P<0.05; Fig. 2I). Moreover, the proportion of
empty bone lacunae at 2 and 4 weeks in the control group was
higher than in the EPO group at corresponding time points
(P<0.05; Fig. 2J). These data are consistent with the hypothesis
that administration of EPO can prevent bone loss in ONFH.
EPO treatment promotes expression of Runx2, osteocalcin,
VEGF and CD31 in ONFH. To further investigate the effect

8758

XU et al: EPO PREVENTS BONE LOSS IN ONFH IN MICE

Figure 1. Micro‑CT analysis of the trabeculae of femoral heads. At 2 weeks, the (A) control, (B) EPO, (C) control and (D) EPO groups. At 4 weeks, the
(E) control and (F) EPO groups. At 6 weeks, the (G) control and (H) EPO groups. At 8 weeks, the (I) control and (J) EPO groups. The trabecular bone in the
EPO treatment group recovered gradually compared with the control group. (K) Quantitative analysis of the bone volume; and (L) bone mineral density in
the control and EPO treatment group at 2, 4, 6 and 8 weeks. The BV/TV and BMD of femoral heads increased in the EPO treatment group at 6 and 8 weeks
compared with the control group. Data are presented as the mean ± standard deviation. *P<0.05 vs. the control group. EPO, erythropoietin; BV/TV, bone
volume/total volume; BMD, bone mineral density; micro‑CT, micro computed tomography.

of EPO on ONFH at 4 and 8 weeks following treatment with
EPO, Runx2, osteocalcin, VEGF and CD31 were examined
in the femoral heads by immunohistochemistry. The authors
of the present study identified that positive signals for Runx2
and osteocalcin were significantly higher in the EPO group
than in the control group (P<0.05; Fig. 3). In addition, an
increased abundance of VEGF‑positive staining was observed
predominantly in the bone marrow cavity of femoral heads
from the EPO group compared with the control group (P<0.05;
Fig. 4A‑E) and the abundance of CD31‑positive staining was
increased in subchondral trabecular bone of necrotic femoral
heads in the EPO group compared with the control group
(Fig. 4F‑I). The analysis of MVD, based on CD31‑positive
staining, demonstrated that few microvessels were present in
subchondral trabecular bones of necrotic femoral heads in the
control group at 4 and 8 weeks, while the number of microvessels in the EPO group increased significantly (P<0.05;
Fig. 4J). These data suggest that EPO can prevent bone loss in
ONFH through enhancing Runx2‑mediated osteogenesis and
VEGF‑mediated angiogenesis.
EPO treatment inhibits apoptosis induced by ONFH. At 4 and
8 weeks following treatment with EPO, TUNEL assays were
performed to verify whether administration of EPO affected
apoptosis associated with ONFH. It was determined that the
treatment with EPO led to decreased abundance of apoptotic
cells, both in the trabecular bone and bone marrow cavity at

the same time points (Fig. 5A‑D). In addition, quantitative
analysis confirmed a significantly increased apoptosis rate
in the control group compared with the EPO group at 4 and
8 weeks (P<0.05; Fig. 5E). These results suggest that the
administration of EPO can inhibit apoptosis in the trabecular
bone and bone marrow cavity in ONFH.
Discussion
ONFH is a multifactorial disease and a leading cause of
mobility impairment. Long‑term administration of GCs
is considered one of the predominant pathological factors
stimulating ONFH development and progression, leading to
disruption of femoral head blood supply in the majority of
cases. Resulting insufficient blood supply further affects the
femoral head and eventually leads to its collapse and the development of hip osteoarthritis in patients (16). At present, there
are no effective treatments for ONFH and the current therapy
focuses on the management of symptoms. Hip replacement
is the only effective treatment of choice. Therefore, there is a
need for alternative interventions to treat ONFH and reduce
patient morbidity and economic impact.
In previous studies, angiogenic and growth factors demonstrated promising effects on bone formation and regeneration
in ONFH, including VEGF, fibroblast growth factors and
hepatocyte growth factor (17‑19). Several angiogenic factors
could in theory be used for clinical treatment, but they could
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Figure 2. Histopathological analysis of the trabecular bone in the femoral head. At 2 weeks, the (A) control, (B) EPO, (C) control and (D) EPO groups. At
4 weeks, the (E) control and (F) EPO groups. At 6 weeks, the (G) control and (H) EPO groups. At 8 weeks, the (I) control and (J) EPO groups. Severely
thinned and disordered trabeculae, large empty bone lacunae and numerous pyknotic nuclei of osteocytes were evident in femoral heads from the control
group, whereas the morphological structure of EPO treatment group relatively improved (magnification, x400). (I) Quantitative analysis of bone volume; and
(J) empty lacunae rate in the control and EPO treatment group at 2, 4, 6 and 8 weeks. The BV/TV of femoral heads increased in the EPO treatment group at 6
and 8 weeks compared with the control group. The empty lacunae rate in femoral heads decreased in the EPO treatment group at 2 and 4 weeks compared with
the control group. Data are presented as the mean ± standard deviation. *P<0.05 vs. the control group. EPO, erythropoietin; BV/TV, bone volume/total volume.

also induce severe complications, including an increased
intraosseous pressure due to vascular permeability, and arterial
obliteration due to vascular smooth muscle proliferation (19).
EPO is one of the most suitable candidates for the treatment
of ONFH since it promotes bone regeneration (3,4) and has
been clinically used for the treatment of chronic anemia with
few side effects (20). However, it has been demonstrated that
systemic administration of EPO can deteriorate blood supply
and blood viscosity as it increases RBC mass, and induces
hypertension and thromboembolic events (21). In addition, a
previous study reported that administration of 5,000 U/kg/day
EPO can significantly increase the hematocrit, which can
aggravate ONFH through impaired blood flow and nutrition
and perfusion (22). In order to avoid these complications, the
authors of the present study decided to intramuscularly administer 500 U/kg/day EPO. During the experimental period, no
systemic side effects were observed.
Results from Micro‑CT and histological analyses clearly
demonstrated that administration of EPO restored microstructure of the femoral head by improving the trabecular bone
volume and reducing the rate of empty lacunae in ONFH.
These observations are consistent with other studies which
demonstrated that EPO treatment can enhance bone regeneration (5). Therefore, EPO treatment can improve ONFH in mice.
In order to further elucidate the mechanism underlying EPO‑induced stimulation of bone formation in vivo,

immunohistochemical analysis of Runx2 and osteocalcin
was performed. Runx2 is a key transcription factor associated with osteoblast differentiation, and osteocalcin is a
biochemical marker secreted by mature osteoblasts (23).
Immunohistochemistry of femoral heads indicated that EPO
treatment up‑regulated the expression of Runx2 and osteocalcin at 4 and 8 weeks. These results suggest that EPO may
stimulate bone formation through Runx2‑mediated osteogenesis. Other beneficial effects of EPO treatment include
increased VEGF‑associated angiogenesis (4). As a significant
component of skeletal development and repair, angiogenesis
contributes to the process of bone development and repair
through adequate formation of new capillaries from existing
vessels (24). In addition, GCs inhibit the expression of VEGF
in femoral heads and consequently limit angiogenesis and
osteogenesis in ONFH induced by GCs (7). Experiments
in vitro demonstrated that primary osteoblasts derived from
clinically osteoarthritic femoral heads displayed downregulation of VEGF following co‑incubation with GCs for 24 h (25).
In the present study, immunohistochemical analysis of VEGF
demonstrated that the expression VEGF can be upregulated
in the femoral heads in ONFH following treatment with EPO,
compared with the control group. CD31, a member of the Ig
superfamily of cell adhesion molecules, is commonly used
to indicate the presence of endothelial cells (26). An analysis
of MVD was performed based on CD31‑positive staining
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Figure 3. Immunohistochemical staining of Runx2 and osteocalcin. For Runx2, the (A) control and (B) EPO groups at 4 weeks, and the (C) control and
(D) EPO groups at 8 weeks. (E) Quantification of Runx2 expression. For osteocalcin, the (F) control and (G) EPO groups at 4 weeks, and the (H) control and
(I) EPO groups at 8 weeks. (J) Quantification of osteocalcin expression levels. Data are presented as the mean ± standard deviation. *P<0.05 vs. the control
group. EPO, erythropoietin; Runx2, runt‑related transcription factor 2; OD, optical density.

in femoral heads and it was demonstrated that microvessels
were increased in the subchondral trabecular bone of necrotic
femoral heads following treatment with EPO for 4 and 8 weeks,
compared with the control group. Taken together, administration of EPO prevented bone loss in ONFH partially by
increasing VEGF‑mediated angiogenesis. It has been reported
that VEGF is important for bone remodeling and regeneration as it effectively couples angiogenesis and osteogenesis in
the bone microenvironment (27), but whether EPO‑induced
osteogenesis is coupled with VEGF remains to be elucidated.
Apoptosis of osteoblasts and osteocytes is a common
pathogenic pathway of GC‑induced ONFH (28). A previous
study suggested that apoptosis partially causes cell death in
the femoral head of patients with ONFH (29). In addition,
O'Brien et al (30) reported that GCs could directly induce
apoptosis of osteoblasts and osteocytes. Moreover, once the
blood supply from collateral circulation is restricted without
enough capillary arterialization in GC‑induced ONFH, the
lack of available oxygen and nutrients may cause apoptosis of
osteoblasts and osteocytes (31). Results of the TUNEL assay
performed in the present study demonstrated that apoptosis
occurred in osteocytes and bone marrow cells in the mice
model of ONFH, while the apoptosis index in the EPO

treatment group was significantly reduced at 4 and 8 weeks,
suggesting that EPO could interfere with apoptosis and prevent
bone loss in steroid‑associated ONFH.
In conclusion, the present study demonstrated that the
administration of EPO prevents bone loss by up‑regulation of
Runx2‑mediated osteogenesis, an increase in VEGF‑mediated
angiogenesis and inhibition of cell apoptosis in the ONFH
mouse model. Therefore, EPO is a promising agent for
the treatment of ONFH. Further research will elucidate
the mechanism underlying the effect of EPO treatment on
the prevention of bone loss during ONFH while avoiding
induction of side effects.
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Figure 4. Immunohistochemical staining of VEGF and CD31 in of the femoral heads. For VEGF, the (A) control and (B) EPO groups at 4 weeks, and the
(C) control and (D) EPO groups at 8 weeks. (E) Quantification of VEGF expression. For CD31, the (F) control and (G) EPO groups at 4 weeks, and the
(H) control and (I) EPO groups at 8 weeks. (J) Quantification of CD31 expression levels. The mean density of VEGF in the EPO treatment group was higher
than that in the control group at 4 and 8 weeks. MVD in the EPO treatment group significantly increased compared with the control group at 4 and 8 weeks.
Data are presented as the mean ± standard deviation. *P<0.05 vs. the control group. VEGF, vascular endothelial growth factor; CD31, platelet endothelial cell
adhesion molecule; EPO, erythropoietin; MVD, microvessel density.

Figure 5. Terminal deoxynucleotidyl‑transferase‑mediated dUTP nick end labeling assays of femoral heads. The (A) control and (B) EPO groups at 4 weeks;
the (C) control and (D) EPO groups at 8 weeks. At 4 and 8 weeks following treatment with EPO, less apoptotic cells were present in the trabecular bone and
bone marrow cavity of the EPO group compared with the control group. The black arrow indicates an apoptotic cell in the trabecular bone and the red arrow
indicates apoptotic cells in the bone marrow cavity. (E) Quantitative analysis of the apoptosis rate in the control and EPO treatment group at 4 and 8 weeks.
A significantly higher apoptosis rate was observed in the control group compared with the EPO treatment group at 4 and 8 weeks. Data were presented as the
mean ± standard deviation. *P<0.05 vs. the control group. EPO, erythropoietin.
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